Malignant Pleural Mesothelioma (mpm) Clinical Trials
2 recruiting trials for Malignant Pleural Mesothelioma (mpm). Eligibility criteria explained in plain English.
TrialFinderData lists 2 Malignant Pleural Mesothelioma (mpm) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 1 (1 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by Nurix Therapeutics, Inc. (1), Azienda USL Reggio Emilia - IRCCS (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is NX-1607 (drug, 1 trial), followed by Paclitaxel.
Track Malignant Pleural Mesothelioma (mpm) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of NX-1607 in Adults With Advanced Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced...
Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a rare and incurable cancer. Most patients are diagnosed with unresectable disease for which treatment options are limited. The lack of...
Explore Other Conditions
Frequently Asked Questions
There are currently 2 clinical trials for Malignant Pleural Mesothelioma (mpm), with 2 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Malignant Pleural Mesothelioma (mpm), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Malignant Pleural Mesothelioma (mpm), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.